DPP4 and type 2 diabetes mellitus: One RCT [30] conducted by Zhang et al. investigated a dipeptidyl peptidase 4 inhibitor (vildagliptin), which involved 48 T2D patients who underwent treatment with vildagliptin (50 mg BID) for 6 months.